Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

Isradapine Parkinson’s 3 year $23 million dollar Study nearly completed

https://health.ucsd.edu/news/releases/Pages/2014-09-30-phase-III-parkinsons-clinical-trial.aspx

“If it proves to be effective, this drug will change the way we treat Parkinson’s disease, and the major advantage of it is that isradipine is already widely available, inexpensive and will allow for rapid translation of our research into clinical practice,” said Tanya Simuni, MD, principal investigator of the study and professor of neurology at Northwestern University Feinberg School of Medicine. “Although we now have very effective symptomatic treatments to manage Parkinson’s, the development of a disease-modifying intervention remains the Holy Grail.”